David Donabedian is an Executive Partner at Longwood Fund where he focuses on biotech and biopharma company creation and therapeutics. He invests across Seed through later stages (Seed, Series A–D), primarily in the United States with a focus on the Greater Boston area. He serves on the boards of Anuncia Inc. and Alcyone Therapeutics Inc., and has invested in companies like Immunitas Therapeutics, Be Biopharma, TScan Therapeutics, KalVista Pharmaceuticals, and Grail. Before Longwood Fund, he was Founding CEO of Newleos Therapeutics; Co‑founder, Start‑up CEO, and Senior Advisor at Solu Therapeutics; Start‑up CEO and Senior Advisor at ImmuneID; Co‑founder, CEO, and Director at Axial Therapeutics; Co‑founder, Start‑up CEO, and Senior Advisor at DEM Biopharma, Inc.; and an Adjunct Lecturer at Brown University. David earned his degree from UNC Kenan‑Flagler Business School and lives in Boston, Massachusetts.
David Donabedian, Executive Partner @ Longwood. Profile with intro opportunities and ranking information.
Not Yet Mapped
We've created a profile for David Donabedian from . Our ranking analysis and additional data will be available once our research is complete.
Rankings and detailed information coming soon
Network Strength
No ranking data available yet.
How to get an intro to David
Map your path to David instantly
Connect your network and Draftboard will automatically find and score the strongest paths to David
That's it. Draftboard does the rest.
Rankings based on connection strength analysis - we ONLY show aggregate data, never specific connection data.